Acrux patent triggers milestone payment

By Melissa Trudinger
Friday, 19 November, 2004

Acrux (ASX:ACR) has received a US$250,000 milestone payment from its partner Vivus triggered by the granting of a US patent extending the coverage of its proprietary transdermal drug delivery system.

The patent provides protection for transdermal drug delivery systems consisting of an effective amount of a therapeutic drug, a dermal penetration enhancer and a volatile liquid, with an area of application that becomes touch-dry within 3 minutes of administration.

CEO Igor Gonda said the patent claims provided strategic protection for the product compared to other transdermal drug delivery systems including patches and gels. Acrux has similar patents pending in other international markets.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd